|
Tuesday, March 23 — 8:00 AM — Thurgood Northeast
Click on the blue numbers in parentheses to display abstracts.
Click the  button next to any title to add to Itinerary Planner...
Section D - Gynecologic Pathology
Chaired By: Patricia Shaw and Ie-Ming Shih
| Time | Title and Authors | Itinerary
Planner |
| 8:00 |
Secretory Cell Outgrowth (SCOUT) in the Distal Fallopian Tube: A Clonal Expansion of Secretory Cells Linked to Cancer Risk?
(1059)
E Chen, M Mehrad, KK Mehra, CP Crum. - Brigham and Women's Hospital, Boston, MA.
|  Add |
| 8:15 |
Morphologic and Immunohistochemical Correlation of Ovarian and Tubal Dysplasia in Prophylactic Oophorectomies from BRCA1/2 Mutation Carriers
(1158)
FM Penault-Llorca, G Chene, MM Dauplat, I Raoelfils, N Lagarde, YJ Bignon, J Dauplat. - Centre Jean Perrin, Clermont-Ferrand, France.
| Add |
| 8:30 |
A 10 Year Review of Primary Fallopian Tube Carcinoma at an Oncology Hospital. A Clinicopathological Study of 58 Cases with Evaluation of Staging and Prognostic Factors
(1043)
I Alvarado-Cabrero, G Picon-Coronel, FO Quijano-Castro. - Mexican Oncology Hospital, Mexico, DF, Mexico.
| Add |
| 8:45 |
Loss of Heterozygosity and Immunohistochemical Analysis of a Subset of Primary Fallopian Tube Carcinomas Arising in the Background of Tubal Intraepithelial Carcinoma from Primary Peritoneal Serous Carcinomas with/without Associated Tubal Intraepithelial Carcinoma
(1062)
M Chivukula, R Edwards, M Nikiforova, G Mantha, K McManus, LA Niemeier. - Magee Women's Hospital of UPMC, Pittsburgh, PA; Magee Women's Hospital of UPMC, Pittsburgh.
| Add |
| 9:00 |
Frequency of Serous Tubal Intraepithelial Carcinoma in Various Gynecological Malignancies-A Study of 290 Consecutive Cases
(1193)
S Tang, K Onuma, P Deb, E Wang, A Lytwyn, M Sur, D Daya. - McMaster University, Hamilton, ON, Canada.
| Add |
| 9:15 |
Upregulation of Potential Oncogenes in Serous Tubal Intraepithelial Carcinoma (STIC)
(1183)
AE Smith Sehdev, RJ Kurman, E Kuhn, IM Shih. - Cascade Pathology, Portland, OR; Johns Hopkins Medical Institution, Baltimore.
| Add |
| 9:30 |
RECESS, EXHIBITS, POSTER SESSION III
| |
| 11:00 |
Comparison of Dysplasia Profiles in Stimulated Ovaries and in Those with a Genetic Risk for Ovarian Cancer
(1060)
G Chene, MM Dauplat, N Lagarde, F Mishellany, I Raoelfils, P Dechelotte, J Dauplat, FM Penault-Llorca. - Centre Jean Perrin, Clermont-Ferrand, France; CHU, Clermont-Ferrand, France.
| Add |
| 11:15 |
High-Grade Serous Carcinoma of the Ovary: Negative but Highly Significant Correlation of PI3K Pathway Activation with Specific Chromosomal Aberrations
(1172)
M Schumann, B Karberg, P Kuhlmann, J Behm, O Buchweitz, A Staebler. - University of Tuebingen, Tuebingen, Germany; Ludwigsburg Hospital, Ludwigsburg, Germany; University of Muenster, Muenster, Germany.
| Add |
| 11:30 |
Diagnostic and Prognostic Value of TP53 Expression in Ovarian High-Grade Serous Carcinomas
(1119)
M Kobel, A Reuss, A DuBois, S Kommoss, F Kommoss, D Gao, SE Kalloger, DG Huntsman, CB Gilks. - University of Calgary/CLS, Calgary, AB, Canada; German Working Group Gynecologic Oncology, Ovary (AGO-OVAR), Wiesbaden, Germany; Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, BC, Canada.
| Add |
| 11:45 |
Clustering of Ovarian High-Grade Serous Carcinoma Based on Estrogen-Induced Gene Expression Predicts Poor Survival
(1170)
M Schlumbrecht, D Urbauer, R Broaddus. - M.D. Anderson Cancer Center, Houston, TX.
| Add |
|
|
